PY2175980A - Método de prepación de cannabinoides - Google Patents

Método de prepación de cannabinoides

Info

Publication number
PY2175980A
PY2175980A PY202102175980A PY2175980A PY2175980A PY 2175980 A PY2175980 A PY 2175980A PY 202102175980 A PY202102175980 A PY 202102175980A PY 2175980 A PY2175980 A PY 2175980A PY 2175980 A PY2175980 A PY 2175980A
Authority
PY
Paraguay
Prior art keywords
cannabinoids
stable
substantially pure
drug
pharmaceutical products
Prior art date
Application number
PY202102175980A
Other languages
English (en)
Spanish (es)
Inventor
James Silcock Alan
Montellano Lopez Alejandro
Simon Loft Michael
Original Assignee
Gw Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gw Res Ltd filed Critical Gw Res Ltd
Publication of PY2175980A publication Critical patent/PY2175980A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0203—Solvent extraction of solids with a supercritical fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/028—Flow sheets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0288—Applications, solvents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/04—Solvent extraction of solutions which are liquid
    • B01D11/0492—Applications, solvents used
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • B01D9/0013—Crystallisation cooling by heat exchange by indirect heat exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0036—Crystallisation on to a bed of product crystals; Seeding
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/004—Fractional crystallisation; Fractionating or rectifying columns
    • B01D9/0045—Washing of crystals, e.g. in wash columns
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PY202102175980A 2020-09-02 2021-09-02 Método de prepación de cannabinoides PY2175980A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2013765.9A GB202013765D0 (en) 2020-09-02 2020-09-02 Method of preparing cannabinoids

Publications (1)

Publication Number Publication Date
PY2175980A true PY2175980A (es) 2022-04-18

Family

ID=72749568

Family Applications (1)

Application Number Title Priority Date Filing Date
PY202102175980A PY2175980A (es) 2020-09-02 2021-09-02 Método de prepación de cannabinoides

Country Status (12)

Country Link
US (2) US12539472B2 (cg-RX-API-DMAC10.html)
EP (1) EP4208273A1 (cg-RX-API-DMAC10.html)
JP (1) JP7763246B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230061484A (cg-RX-API-DMAC10.html)
CN (1) CN116056773B (cg-RX-API-DMAC10.html)
AU (1) AU2021338469A1 (cg-RX-API-DMAC10.html)
CA (1) CA3190849A1 (cg-RX-API-DMAC10.html)
GB (2) GB202013765D0 (cg-RX-API-DMAC10.html)
MX (1) MX2023002535A (cg-RX-API-DMAC10.html)
PY (1) PY2175980A (cg-RX-API-DMAC10.html)
TW (1) TW202222299A (cg-RX-API-DMAC10.html)
WO (1) WO2022049007A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB202009321D0 (en) 2020-06-18 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2597321A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
EP4006006A1 (en) * 2020-11-27 2022-06-01 Bridge Farm Nurseries Limited Production of cannabidiol from hemp using subcritical liquid carbon dioxide
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
CA3264785A1 (en) 2022-08-12 2024-02-15 Jazz Pharmaceuticals Research Uk Limited ORAL SOLID DOSAGE FORMS CONTAINING CANNABINOIDS
GB202416518D0 (en) 2024-11-08 2024-12-25 Jazz Pharmaceuticals Research Uk Ltd Combination therapy

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000078979A (ja) 1998-09-04 2000-03-21 Taisho Pharmaceut Co Ltd テトラヒドロカンナビノール酸シンターゼ遺伝子
JP2001029082A (ja) 1999-07-22 2001-02-06 Yukihiro Masayama カンナビジオール酸シンターゼをコードするdna
DE10051427C1 (de) 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
DK1361864T3 (en) 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
US10538373B2 (en) 2002-08-14 2020-01-21 Gw Pharma Limited Pharmaceutical formulation
MXPA05001621A (es) 2002-08-14 2005-08-19 Gw Pharma Ltd Extraccion de cannabinoides farmaceuticamente activos de materiales vegetales.
GB2393182B (en) 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
CN101193884A (zh) 2005-06-13 2008-06-04 惠氏公司 微管蛋白抑制剂和其制备方法
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
MY148798A (en) * 2005-11-08 2013-05-31 Suntory Holdings Ltd Method of refining episesamin
KR101650584B1 (ko) * 2007-08-31 2016-08-23 디에스엠 아이피 어셋츠 비.브이. 다중불포화된 지방산 함유 고체 지방 조성물 및 그의 용도 및 생산
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2475183B (en) 2008-06-04 2011-11-23 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agent that are selective estrogen receptor modulators
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Gw伐瑪有限公司 使用植物大麻素次大麻二酚(cbdv)來治療癲癇之用途
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
EP2500072A1 (en) * 2011-03-15 2012-09-19 LEK Pharmaceuticals d.d. A novel process of residual solvent removal
CN102351628B (zh) * 2011-08-10 2014-04-16 济南卡博唐生物科技有限公司 从异己烷和甲醇混合溶剂中除去甲醇的方法
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US8604062B2 (en) * 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
GB2504263B (en) 2012-06-08 2015-09-16 Gw Pharma Ltd Synergistic therapies for neuroprotection
CN102925295A (zh) * 2012-10-30 2013-02-13 陕西启源科技发展有限责任公司 一种利用餐饮废油生产生物柴油的制备方法
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
GB2516814B (en) 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527591A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd 7-hydroxy cannabidiol (7-OH-CBD) for use in the treatment of non-alcoholic fatty liver disease (NAFLD)
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531283A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiols in the treatment of degenerative skeletal muscle diseases
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531280A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
US11034639B2 (en) * 2015-01-22 2021-06-15 Phytoplant Research S.L. Methods of purifying cannabinoids using liquid:liquid chromatography
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2542155B (en) 2015-09-09 2018-08-01 Gw Pharma Ltd Use of cannabidiol in the treatment of mental disorders
GB2542797A (en) 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2551985B (en) 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US10155176B1 (en) 2016-11-03 2018-12-18 Healer, LLC Process for the production of a concentrated cannabinoid product
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
CN110678481B (zh) 2017-03-16 2023-10-31 伊沃芙生物制品公司 用于纯化白蛋白的方法
CN107011125B (zh) * 2017-05-06 2020-07-28 云南汉木森生物科技有限责任公司 一种富集大麻二酚的方法
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
US9919241B1 (en) 2017-06-27 2018-03-20 Entheo Gardens Inc Extraction method
US10189762B1 (en) 2017-07-07 2019-01-29 Orochem Technologies, Inc. Process for purification and separation of cannabinoids, from dried hemp and cannabis leaves
IT201700085508A1 (it) 2017-07-26 2019-01-26 Inalco S R L Metodo per la produzione di cannabinoidi da varietà di canapa industriale
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2568471B (en) 2017-11-15 2022-04-13 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2572125B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2572126B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB2572737A (en) 2018-01-24 2019-10-16 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2019195752A1 (en) * 2018-04-05 2019-10-10 Canopy Holdings, LLC Hemp powder
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
WO2020028198A1 (en) * 2018-08-03 2020-02-06 Biomass Oil Separation Solutions, Llc Processes and apparatus for extraction of substances and enriched extracts from plant material
GB2579179A (en) 2018-11-21 2020-06-17 Gw Res Ltd Cannabidiol-type cannabinoid compound
CA3138732A1 (en) 2018-11-30 2020-06-04 Canopy Growth Corporation Water-soluble formulations of cannabinoids or cannabis-derived compounds, methods of making and use
GB2580881A (en) 2018-11-30 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US10413845B1 (en) * 2018-12-14 2019-09-17 Socati Technologies Processes for solvent extraction of cannabinoids, terpenes and flavonoids from biomass
US10414709B1 (en) * 2018-12-14 2019-09-17 Socati Technologies Processes for solvent extraction of cannabinoids, terpenes and flavonoids from biomass
GB2580653A (en) 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
GB2581517A (en) 2019-02-22 2020-08-26 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2581987B (en) 2019-03-06 2021-11-17 Gw Res Ltd Use of cannabidiol in combination with antibiotics
GB2584140A (en) 2019-05-23 2020-11-25 Gw Res Ltd Use of cannabidiol in the treatment of epileptic spasms
GB2584341B (en) 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations
CN110304994B (zh) * 2019-07-01 2022-04-01 吴平 一种从工业大麻中提取高纯度大麻二酚的方法
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2586026A (en) 2019-07-29 2021-02-03 Gw Res Ltd Use of cannabidol in the treatment of Dravet syndrome
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
GB2588461A (en) 2019-10-25 2021-04-28 Gw Res Ltd Use of cannabidiol preparations in the treatment of absence epilepsy
GB2588457B (en) 2019-10-25 2022-12-21 Gw Res Ltd Cannabinoid compound
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB201916977D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB201918846D0 (en) 2019-12-19 2020-02-05 Gw Res Ltd Oral cannabinoid formulations
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US20210370198A1 (en) * 2020-05-29 2021-12-02 Chemtor, Lp Purification and extraction of cannabinoids
US20220087951A1 (en) 2020-09-18 2022-03-24 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US11815187B2 (en) 2022-01-26 2023-11-14 Maag Germany Gmbh 3-port valve

Also Published As

Publication number Publication date
TW202222299A (zh) 2022-06-16
US20240293762A1 (en) 2024-09-05
US20260166448A1 (en) 2026-06-18
MX2023002535A (es) 2023-03-14
EP4208273A1 (en) 2023-07-12
AU2021338469A1 (en) 2023-03-23
JP7763246B2 (ja) 2025-10-31
GB202013765D0 (en) 2020-10-14
KR20230061484A (ko) 2023-05-08
GB2600528A (en) 2022-05-04
CN116056773B (zh) 2026-07-24
JP2023539898A (ja) 2023-09-20
CA3190849A1 (en) 2022-03-10
WO2022049007A1 (en) 2022-03-10
GB202112397D0 (en) 2021-10-13
US12539472B2 (en) 2026-02-03
CN116056773A (zh) 2023-05-02

Similar Documents

Publication Publication Date Title
MX2023002535A (es) Metodo para preparar cannabinoides.
MX2024004921A (es) Derivados de piperidinilindol, metodos de preparacion y usos medicinales de estos.
MX2026002446A (es) Compuestos macrociclicos, metodo de preparacion de estos y uso de estos
MX2020012041A (es) Formulacion farmaceutica.
AR086409A1 (es) Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino
MX2017011280A (es) Terapia neuro-afectiva regional topica con cannabinoides.
ES3064032T3 (en) Ophthalmological compositions comprising brimonidine and ketotifen for use in the treatment of allergies
DOP2017000105A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
MX2018002461A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
MX2022005985A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
BR112015010980A2 (pt) composição de excipientes e formas farmacêuticas de libertação prolongada com aumento de biodisponibilidade de drogas antibacterianas, drogas anticoccidianas e outros medicamentos para aves e suínos comerciais
AR122059A1 (es) Usos y formulaciones de cannabinoides
CY1124893T1 (el) Φαρμακευτικο μeιγμα μαροπιταντης
DOP2024000203A (es) Composición que comprende n-acetilcisteína, vitamina d y preferentemente glutatión, usos de la misma, y composiciones farmacéuticas y nutracéuticas de los mismos
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
MX2017016719A (es) Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada.
MX2021004138A (es) Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias.
MX362885B (es) Pastilla para tratar garganta irritada, ronquera y tos seca asociada, y enfermedades inflamatorias de la cavidad oral y faringea.
CL2021002874A1 (es) Formas de dosificación sólidas farmacéuticas o nutracéuticas de múltiples capas que comprenden pirimidina y/o derivados de purina y vitaminas b, preparación y usos de las mismas
MX2024001659A (es) Composiciones y métodos para el tratamiento de la sobredosis por opioides.
UY40329A (es) Formulación con oxitocina
CO2022012880A2 (es) Composiciones de palmitato de vitamina a, procesos para su preparación, usos y métodos que las componen
JOP20250001A1 (ar) تركيبات صيدلانية تشتمل على آيزوتريتينوين وعمليات تحضيرها واستخداماتها
MX2021001820A (es) Composicion farmaceutica para la liberacion controlada de farmacos acidos debiles y usos de los mismos.
MX2021008329A (es) Farmaco profilactico o terapeutico para enfermedades neurodegenerativas.